The neurocutaneous illness known as herpes zoster, or shingles, is predominantly caused by the reactivation of the varicella-zoster virus (VZV). Usually, after an early-life VZV infection, a latent infection in the dorsal sensory or cranial nerve ganglia causes this reactivation. When the virus reactivates, it travels to the skin via a neural route and causes the emergence of a recognizable rash. Red rashes arise shortly after the onset of initial symptoms, which are usually limited to one side of the body and include pain and burning. The Polymerase Chain Reaction (PCR) is considered the gold standard for herpes zoster diagnosis because of its exceptional sensitivity and specificity.
Global Herpes Zoster Treatment Market Driving Factors and Challenges
The primary drivers of the varicella zoster infection treatment market expansion are the rising rates of virally-borne diseases in children and the elderly, the high infection transmission rate, the prevalence of infections in low- and middle-income nations, and the expanding profits of industry participants. By releasing their goods and aiming for maximum market share, the firms in the varicella zoster infection treatment market are focused on both organic and inorganic growth. Additionally, it is anticipated that capacities for research and development, portfolio expansion, and acquisitions will open doors for market expansion.
The elderly population is an intensive care population, and the onset of viral diseases like Herpes zoster increases the risk of associated infections and other reactions. As a result, the adverse effects of anti-viral therapy treatment among this population present a major challenge to the market's growth. Further challenging the varicella zoster infection treatment market may be the availability of alternative therapy options for treating herpes zoster and varicella, such as homeopathy, vitamins, and other natural herbal treatments.
Impact of COVID-19 on Global Herpes Zoster Treatment Market
COVID-19 had a major effect on the market's expansion. Reactivation of the varicella-zoster virus, which can happen in people with immunosuppressive conditions or aging-related reductions in cell-mediated immunity, is the cause of herpes zoster infection. A coronavirus infection can cause Herpes zoster reactivation and has also been connected to T-cell immunological dysfunction. Because COVID-19 tends to create an immunosuppressive state due to functional impairment and a corresponding quantitative decrease in T lymphocytes, particularly cd4+ T cells, cd8+ T cells, and natural killer cells, patients with the virus were more likely to reactivate herpes zoster.
Herpes Zoster Treatment Market Key Players:
The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as Abbott Laboratory, Bausch Health, Cipla Inc, Camber Pharmaceuticals, GlaxoSmithKline plc, Merck & Co, Novartis AG, Pfizer Inc, Eli Lilly and Co, and Teva Pharmaceutical Industries Ltd.
Global Herpes Zoster Treatment Market Segmentation:
By Treatment Type: Based on the Treatment Type, Global Herpes Zoster Treatment Market is segmented as; Antiviral Medications, Anti-inflammatory, Medications, Others.
By Route of Administration: Based on the Route of Administration, Global Herpes Zoster Treatment Market is segmented as; Oral, Topical.
By Distribution Channel: Based on the Distribution Channel, Global Herpes Zoster Treatment Market is segmented as; Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers
By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.